Polaryx Therapeutics, Inc./$PLYX

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Polaryx Therapeutics, Inc.

Polaryx Therapeutics Inc is a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric LSDs. Its therapeutic approach focuses on treating the underlying pathophysiology of these diseases and addressing unmet needs. The company's therapeutic pipeline includes PLX-200, PLX-300, and PLX-100, which are orally available small-molecule drug candidates designed to address core pathological mechanisms common to LSDs. The Company has one reportable segment: lysosomal storage disorders. The lysosomal storage disorders segment consists of the Company's costs associated with the preclinical and clinical development of the Company's product candidates.

Ticker

$PLYX
Sector
Health
Primary listing
NASDAQ

Employees

7
Headquarters
Paramus, United States
Website
polaryx.com

PLYX Metrics

BasicAdvanced
$133m
-
-$0.14
-
-

What the Analysts think about PLYX

Analyst ratings (Buy, Hold, Sell) for Polaryx Therapeutics, Inc. stock.

PLYX Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37bn
-39.75%
Net income
$45bn
107.52%
Profit margin
37.65%
6.78%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs